摘要
目的观察人参皂苷联合替莫唑胺治疗脑胶质瘤术后患者的临床疗效及其对脑脊液干细胞生长因子(HGF)、TNF-α、IL-17水平的影响。方法将90例脑胶质瘤术后患者随机分为试验组和对照组,各45例;对照组给予替莫唑胺治疗,试验组在对照组基础上口服人参皂苷Rg3,疗程为6个治疗周期。比较两组总生存期(OS)、无进展生存时间(PFS)及治疗前后脑脊液HGF、TNF-α、IL-17的水平变化。结果治疗后,试验组OS和PFS显著长于对照组(P<0.05);治疗后,两组患者脑脊液HGF、TNF-α、IL-17水平较治疗前均显著降低(P<0.05,P<0.01),且试验组HGF、TNF-α、IL-17水平显著低于对照组(P<0.05)。结论人参皂苷Rg3联合替莫唑胺可抑制脑胶质瘤的生长增殖而延长患者生存期。
Objective To observe the clinical efficacy and influence of ginsenoside combined with temozolomide on the levels of HGF, TNF-α and IL- 17 in cerebrospinal fluid of postoperative patients with brain glioma. Methods 90 postoperative patients with brain glioma were divided into the treatment group and the control group,45 cases in each group. The control group was treated with temozolomide, the treatment group was treated with ginsenoside Rg3 based on the treatment for control group,with a course of 6 treatment cycles. The overall survival （OS）, progression-free survival （PFS）, and the levels of HGF, TNF-α and IL-17 in cerebrospinal fluid before and after treatment were compared. Results After treatment,the OS and PFS in the treatment group were significantly longer than those in the control group （ P 〈 0. 05 ） ; after treatment, the levels of HGF, TNF-α and IL- 17 in cerebrospinal fluid of patients in both groups were significantly decreased compared with the treatment before （P 〈 0. 05, P 〈 0.01 ）, and the levels of HGF, TNF-α and IL-17 in the treatment group were significantly lower than those in the control group （ P 〈 0. 05 ）. Conclusion Ginsenoside Rg3 combined with the temozolomide can inhibit the growth and proliferation of brain glioma and prolong the survival time of patients.
出处
《上海中医药杂志》
2017年第1期50-52,共3页
Shanghai Journal of Traditional Chinese Medicine
基金
浙江省自然科学基金项目(LY12H16032)
作者简介
吴斌，男，硕士，主治医师，主要从事脑胶质瘤的基础与临床研究工作
